{
  "kind": "treatment",
  "slug": "lormetazepam",
  "type": "hypnotic",
  "name": "Lormetazepam",
  "summary": "A short-acting benzodiazepine hypnotic used primarily for the short-term treatment of insomnia.",
  "description": "Lormetazepam is a benzodiazepine with strong hypnotic and sedative effects, indicated for short-term management of severe insomnia. It has a relatively rapid onset of action and an intermediate half-life, making it effective for sleep initiation and maintenance without excessive next-day sedation in most patients.",
  "category": "medications/hypnotics",
  "tags": [
    "benzodiazepine",
    "hypnotic",
    "sedative",
    "insomnia"
  ],
  "metadata": {
    "drug_classes": [
      "Benzodiazepine",
      "Hypnotic",
      "Sedative"
    ],
    "therapeutic_categories": [
      "Sleep Disorders"
    ],
    "mechanism_categories": [
      "GABA"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": true,
    "brand_names": [
      "Noctamid"
    ],
    "dea_schedule": "Schedule IV (in countries where applicable)",
    "fda_pregnancy_category": "D",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Sleep Medicine"
    ],
    "fda_approval_year": 1980
  },
  "clinical_metadata": {
    "primary_indications": [
      "Insomnia"
    ],
    "off_label_uses": [
      "Preoperative sedation"
    ],
    "contraindications": [
      "Hypersensitivity to benzodiazepines",
      "Severe respiratory insufficiency",
      "Sleep apnea syndrome",
      "Acute narrow-angle glaucoma",
      "Myasthenia gravis"
    ],
    "monitoring_required": [
      "Daytime sedation",
      "Signs of dependence and misuse",
      "Respiratory status in at-risk patients"
    ],
    "efficacy_rating": {
      "insomnia": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "lormetazepam",
      "noctamid",
      "benzodiazepine",
      "hypnotic",
      "sedative"
    ],
    "synonyms": [
      "lormetazepamum"
    ],
    "common_misspellings": [
      "lormetazapam",
      "lormetazepan"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Severe insomnia (short-term use)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Enhances the activity of GABA at the GABA-A receptor, increasing chloride influx and neuronal hyperpolarization, resulting in sedation and hypnosis."
    },
    {
      "type": "dosing",
      "adult": {
        "insomnia": "0.5–2 mg at bedtime; use the lowest effective dose"
      },
      "geriatric": "Start with 0.5–1 mg at bedtime",
      "hepatic_impairment": "Use with caution; lower doses recommended",
      "renal_impairment": "Use with caution in severe impairment"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 0.5 mg, 1 mg, 2 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset: 30–60 minutes; Duration: 6–8 hours."
    },
    {
      "type": "adverse_effects",
      "common": [
        "drowsiness",
        "dizziness",
        "ataxia",
        "anterograde amnesia"
      ],
      "less_common": [
        "headache",
        "confusion",
        "fatigue"
      ],
      "serious": [
        "respiratory depression",
        "paradoxical agitation",
        "dependence and withdrawal symptoms"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Concomitant use with opioids can cause profound sedation, respiratory depression, coma, and death.",
      "other": [
        "Risk of misuse, abuse, and dependence",
        "Avoid abrupt discontinuation after prolonged use",
        "May cause next-day psychomotor impairment"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Opioids",
          "risk": "Severe CNS depression",
          "action": "Avoid or monitor closely"
        },
        {
          "with": "Alcohol",
          "risk": "Additive sedation and respiratory depression",
          "action": "Avoid"
        },
        {
          "with": "Other CNS depressants",
          "risk": "Enhanced sedative effects",
          "action": "Use caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Daytime alertness",
        "Signs of dependence and misuse",
        "Respiratory status in at-risk patients"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Avoid unless absolutely necessary; risk of fetal harm and neonatal withdrawal",
      "lactation": "Excreted in breast milk; may cause sedation in infants",
      "pediatrics": "Not recommended",
      "geriatrics": "Increased sensitivity; start with lowest dose"
    },
    {
      "type": "tapering",
      "text": "Reduce dose gradually over 1–2 weeks to avoid withdrawal symptoms such as rebound insomnia, anxiety, and tremors."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Short half-life reduces next-day sedation risk compared to longer-acting benzodiazepines",
        "Best reserved for severe insomnia not responsive to non-pharmacologic interventions",
        "High potential for dependence; avoid long-term use"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "European Medicines Agency Product Information",
          "url": "https://www.ema.europa.eu/"
        },
        {
          "label": "British National Formulary",
          "url": "https://bnf.nice.org.uk/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Lormetazepam: Dosing, Side Effects, Interactions",
    "description": "Lormetazepam is a short-acting benzodiazepine used for insomnia. Learn about its dosing, effects, risks, and precautions."
  }
}
